PHI expands into Australia and respiratory research

In April Phase Holographic Imaging (PHI) had outstanding orders of approx­imately 2 MSEK, consisting of 13 HoloMonitor M4 units and 15 orders for the recently launched motorized stage. A portion of these units have now been delivered. Among others, a HoloMonitor M4 with motorized stage has been delivered to one of the leading institutes for respiratory research in Australia – the Woolcock Institute of Medical Research.

To improve the understanding of the mechanisms behind asthma the Respi­ratory Cellular and Molecular Biology Group will measure volume changes in respiratory muscle cells using PHI’s HoloMonitor technology. The ability to effortlessly measure changes in cell volume is one of the unique and innovative advantages of HoloMonitor technology.

“We see a limited value in reporting individual orders and deliveries that lack strategic value to our investors. However, this installation is of strategic value as it is our first instrument on the Australian continent. Additionally, the order opens up a new market for us – respiratory research”, says Peter Egelberg, CEO of PHI.


Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
+46 46 38 60 80

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
+1 617-963-5150


VAT: SE556542781101

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2